Aytu BioPharma, Inc.
Balance Sheet
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $26.3M | $31.0M | $20.0M | $23.0M | $19.4M | $49.6M | $48.1M | $11.0M |
| Accounts Receivable | $22.8M | $31.2M | $23.5M | $28.9M | $21.7M | $28.2M | $5.6M | $1.7M |
| Inventory | $6.9M | $11.4M | $12.1M | $12.0M | $10.8M | $16.3M | $10.0M | $1.4M |
| Total Current Assets | $61.8M | $79.2M | $61.9M | $72.8M | $59.9M | $105.2M | $75.4M | $15.4M |
| Property, Plant & Equipment | $385.0K | $532.0K | $693.0K | $1.8M | — | — | $258.5K | $203.7K |
| Goodwill | — | — | — | $0 | $0 | $65.8M | $28.1M | $0 |
| Intangible Assets (Excl. Goodwill) | $41.4M | $42.2M | $52.5M | $59.0M | $70.6M | $85.5M | $48.9M | $19.1M |
| Total Assets | $105.0M | $124.2M | $118.1M | $136.5M | $137.6M | $265.7M | $153.3M | $34.7M |
| Liabilities | ||||||||
| Accounts Payable | $11.3M | $10.6M | $10.3M | $13.5M | — | $19.3M | $11.6M | $2.1M |
| Total Current Liabilities | $54.7M | $63.1M | $62.2M | $69.0M | $64.4M | $109.4M | $28.8M | $5.4M |
| Long-Term Debt | $9.1M | $10.9M | $10.9M | $14.7M | $15.0M | $180.0K | $0 | — |
| Total Liabilities | $69.7M | $105.2M | $90.4M | $97.1M | $93.3M | $128.1M | $58.3M | $27.6M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-347.8M | $-333.5M | $-320.0M | $-304.1M | $-287.1M | $-178.3M | $-120.0M | $-106.4M |
| Total Stockholders' Equity | $35.3M | $19.0M | $27.7M | $39.4M | $44.3M | $137.6M | $95.0M | $7.1M |